

IMMUNOTHERAPY BRIDGE

Naples, Italy

November 29th - 30th, 2023

SCIENTIFIC RATIONAL

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

PRELIMINARY SCIENTIFIC PROGRAM

**Speakers invited*

***Not included on CME accredited program*

November 29th, 2023

Welcome Coffee and Registration**

10:15 10:20 Introduction and objectives, *Paolo A. Ascierto*

SITC Session – CELL THERAPIES

Chairpersons: *Leisha A. Emens, Bernard A. Fox*

10:20 10:35 CAR-T, *Marcela Maus*

10:35 10:40 Q&A

10:40 10:55 Novel CD4 T cell-based therapies, *Chrystal Paulos*

10:55 11:00 Q&A

11:00 11:15 B Cell, *Tullia Bruno*

11:15 11:20 Q&A

11:20 11:35 Myeloid-induced immune deviation in pancreatic cancer, *Vincenzo Bronte*

11:35 11:40 Q&A

11:40 11:55 Best of SITC 2023 for clinical development and trials, *Paolo A. Ascierto*

11:55 12:00 Q&A

12:00 12:30 LECTURE

12:30 1:20 SYMPOSIUM

1:20 2:15 Lunch**

Session 2 - TRENDS AND BIOMARKERS IN IMMUNOTHERAPY

Chairpersons: *Alfredo Budillon, Luigi Buonaguro*

2:15 2:30 Head and Neck Cancer: novel therapies and biomarkers of response, *Robert L. Ferris*

2:30 2:35 Q&A

2:35 2:50 Immunotherapy in GU, *James L. Gulley*

2:50 2:55 Q&A

2:55 3:10 Novel biomarkers of ICI in metastatic melanoma, *Tomas Kirchoff**

3:10 3:15 Q&A

3:15 3:30 Novel insights into the mechanisms of radiation-induced anti-tumor immunity
Sandra Demaria

3:30 3:35 Q&A



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

3:35 4:05 Trends in hematological cancers:
the treatment of Leukemia, *Marco Ruella*
the treatment of Lymphoma, *Joshua Brody**

4:05 4:10 Q&A

4:10 4:25 Non melanoma skin cancers, *Paolo A. Ascierto*

4:25 4:30 Q&A

4:30 4:45 Coffee Break**

4:45 5:00 Title to be defined, *Sergio Quezada**

5:00 5:05 Q&A

5:05 5:20 New perspectives in genomic field, *Carlo Bifulco*

5:20 5:25 Q&A

5:25 5:40 Radiotherapy, *Silvia Formenti*

5:40 5:45 Q&A

GREAT DEBATE Session

Chairpersons: *Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov*

5:45 6:15 Are MDSC important in affecting cancer progression?
Lisa Coussens VS Dmitry Gabrilovich**

6:15 6:25 Discussion

6:25 6:55 Cancer vaccines Vs Adoptive Cell therapy
Pawel Kalinski VS Allison Betof Warner

6:55 7:05 Discussion

7:05 7:35 Bispecific VS combination therapy
Pablo Humana, Yvonne Chen**

7:35 7:45 Discussion

November 30th, 2023

09:00 09:30 Welcome coffee**

Session 3 - ORGAN SPECIFIC IMMUNE RESPONSE

Chairpersons: *John Haanen*, Omid Hamid*

09:30 09:40 Efforts to achieve immune mediated tumor eradication in the CNS, *Bart Neyns*

09:40 09:50 GU, *Akash Patnaik**

09:50 10:00 Liver, *Piera Federico**

10:00 10:10 Innovating immunotherapy for gastrointestinal cancers, *Gregory B. Lesinski*



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

10:10 10:20 Lung, *Helene Salmon**
10:20 10:30 Breast, *Elisabeth Mittendorf**
10:30 10:40 Ovarian cancer, *Kunle Odunsi*
10:40 11:20 Panel Discussion

GREAT DEBATE Session

Chairpersons: *Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov*

11:20 11:50 Neo-antigens VS alternative antigens
*Stephen Schoenberger VS Nina Bhardwaj**
11:50 12:00 Discussion
12:00 12:30 Immunoscore VS Genes signature
*Jerome Galon VS Allan Venook**
12:30 12:40 Discussion
12:40 1:10 TCR engagers VS CAR-T
*Rom Leidner VS Christopher Klebanoff**
1:10 1:20 Discussion

1:20 2:20 Lunch**

2:20 3:10 SYMPOSIUM

Non Melanoma Skin Cancer, Paolo A. Ascierto

Session 4 - NeoAdjuvant Immunotherapy

Chairpersons: *Paolo A. Ascierto, Elizabeth Burton*

3:10 3:20 Fine-Tuning Neoadjuvant Immunotherapy for Triple Negative Breast Cancer
Leisha A. Emens
3:20 3:30 Advances in Neoadjuvant and Perioperative Immunotherapy for Resectable Non-small Cell
Lung Cancer, *Tina Cascone*
3:30 3:40 CRC, *Myrian Chalabi*
3:40 4:00 Skin Cancers:
Melanoma, *Georgina Long*
Non melanoma skin cancer, *Neil Gross**
4:00 4:10 Multiplex immunofluorescence assays for predicting response to anti-PD-1-based therapies
Janis Taube
4:10 4.20 Validation of a pan-tumor scoring system of pathologic response to neoadjuvant
immunotherapy: update on SITC effort, *Julie Stein Deutch*
4:20 5:00 Discussion

5:00 Conclusions, *Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov*



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

PRESIDENCY

Paolo A. Ascierto, Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Leisha A. Emens, Professor of Medicine, Director of Translational Immunotherapy for the Women’s Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women’s Hospital, Pittsburgh, PA, US

Bernard A. Fox, Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Igor Puzanov, Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala, Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto, Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Carlo Bifulco, Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory; Director, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Elizabeth M. Burton, Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield, Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

Corrado Caracò, Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Mary Dean, Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

Sandra Demaria, Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

Reinhard Dummer, Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Alexander M.M. Eggermont, Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical & Translational Immunotherapy, Utrecht University, Utrecht, Netherland

Leisha A. Emens, Professor of Medicine, Director of Translational Immunotherapy for the Women’s Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women’s Hospital, Pittsburgh, PA, US



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

Bernard A. Fox, Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon, Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Claus Garbe, Professor of Dermatology; President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

Jeffrey E. Gershenwald, Professor of Cancer Biology, Departments of Surgical Oncology and Cancer Biology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Houston, TX, US

Omid Hamid, Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

Giuseppe Masucci, Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin, Full Professor, Chair of Precision Oncology Center, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

Iman Osman, Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri, Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow, Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov, Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Magdalena Thurin, Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington, Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.